Insider Transactions in Q3 2024 at Anaptysbio, Inc (ANAB)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,500
-8.88%
|
$57,000
$38.67 P/Share
|
|
Sep 23
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+8.15%
|
$27,000
$18.5 P/Share
|
|
Sep 17
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,780
-53.85%
|
$143,640
$38.41 P/Share
|
|
Sep 16
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,220
-49.85%
|
$476,580
$39.53 P/Share
|
|
Sep 16
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+40.41%
|
$200,000
$20.16 P/Share
|
|
Sep 16
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,220
-12.6%
|
$84,360
$38.93 P/Share
|
|
Sep 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,720
-34.37%
|
$340,080
$39.53 P/Share
|
|
Sep 16
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+27.0%
|
$70,000
$14.02 P/Share
|
|
Sep 15
2024
|
John A Orwin |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+28.05%
|
-
|
|
Sep 14
2024
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+46.28%
|
-
|
|
Sep 14
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+25.4%
|
-
|
|
Sep 14
2024
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+35.84%
|
-
|
|
Aug 14
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-14.69%
|
$80,000
$40.0 P/Share
|
|
Aug 14
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+12.81%
|
$36,000
$18.5 P/Share
|
|
Aug 14
2024
|
Eco R1 Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
273,972
+3.4%
|
$9,862,992
$36.5 P/Share
|
|
Jul 18
2024
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,500
-11.43%
|
$52,500
$35.0 P/Share
|
|
Jul 18
2024
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+10.26%
|
$27,000
$18.5 P/Share
|
|
Jul 15
2024
|
Hollings Renton |
SELL
Open market or private sale
|
Direct |
10,000
-59.6%
|
$300,000
$30.74 P/Share
|
|
Jul 15
2024
|
Hollings Renton |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+45.56%
|
$60,000
$6.93 P/Share
|